Lastly, potential drug therapies could also target different mitochondrial enzymes and mtROS inhibition to further inhibit the downstream effects of NLRP3 inflammasome activation to see if they provide positive benefits for SJS/TEN patients. The gene discussed is NLRP3; the disease is Schwartz-Jampel syndrome.